Last reviewed · How we verify
NCT04659460
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
NA trial testing Remote Ischemic Conditioning in COVID in 30 participants. Status unknown.
31 March 2021
Quick facts
| Lead sponsor | Unity Health Toronto |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 December 2020 |
| Primary completion | 31 March 2021 |
| Estimated completion | 1 September 2021 |
Drugs / interventions tested
- Remote Ischemic Conditioning
Conditions studied
- COVID — all drugs for COVID →
- Corona Virus Infection — all drugs for Corona Virus Infection →
- Acute Lung Injury — all drugs for Acute Lung Injury →
- Ischemia Limb — all drugs for Ischemia Limb →
Sponsor
Unity Health Toronto — full company profile →
Who can join
16 and older, any sex, with COVID or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease. An excessive and counterproductive systemic inflammatory response is thought to be a major cause of severe disease and death in patients with COVID-19. Severe ICU cases frequently have markedly higher levels of inflammatory markers such as CRP, IL-6, IL and TNF-a; which is thought to be correlated with increasing disease severity. The relationship between dysregulated inflammatory processes and disease states such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are well understood. ALI is characterized by an acute exaggerated mononuclear/neutrophilic inflammatory response followed by progressive collagen deposition in the lung, and if severe enough, may progress to ARDS requiring ventilation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04659460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remote Ischemic Conditioning
Trials testing the same drug.
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT06082583 — The Efficacy of Combination of Traditional Tibetan and Remote Ischemic Conditioning on High Altitude Polycythemia · Phase 2, PHASE3 · unknown
- NCT05653505 — Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis · not yet recruiting
- NCT05379218 — RIC in HIE: A Safety and Feasibility Trial · NA · completed
- NCT04266639 — Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke · NA · completed
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Unity Health Toronto trials
Trials by the same sponsor.
- NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
- NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
- NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
- NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
- NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04659460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
- Last refreshed: 9 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing